Trials / Unknown
UnknownNCT03605056
Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM
Chindamide in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma, a Phase II Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- Peng Liu · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of combination of Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | chidamide | 20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle |
| DRUG | lenalidomide | 25 mg/d, will be administered orally on Days 1-14 each 21 day cycle |
| DRUG | dexamethasone | 40mg weekly, will be administered orally or intravenously |
Timeline
- Start date
- 2018-07-31
- Primary completion
- 2020-07-31
- Completion
- 2022-07-31
- First posted
- 2018-07-30
- Last updated
- 2018-07-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03605056. Inclusion in this directory is not an endorsement.